The 510(k) decision clears the device for use with ultra-rapid-acting insulins from Eli Lilly and Novo Nordisk.
MARKHAM, Ontario--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ ...
Mattel partnered with leading diabetes organization Breakthrough T1D to ensure that the medical devices were accurate The doll, which retails for $10.99, comes with a continuous glucose monitor and ...
Mattel’s new Barbie doll is a Type 1 diabetic with an insulin pump and glucose monitor on her arm. The new brunette Barbie is the latest in a line of dolls the American toy giant has rolled out, ...
“The commercial availability of this new offering is a testament to our decade-long partnership with Dexcom and shared commitment to continued leadership in advancing AID systems,” said Mark Novara, ...
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ ...
Tandem Diabetes Care (TNDM) begins global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus CGM sensor, expanding choice and personalization for people living with ...
Detailed price information for Senseonics Holdings Inc (SENS-Q) from The Globe and Mail including charting and trades.
The Omnipod 5 will be immediately available for people ages 6 to 70. A new technology for people with Type 1 diabetes, one that has been nearly a decade in the making, has been approved by the U.S.
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) ...
Mattel announced the release of the first-ever Barbie doll with type 1 diabetes, complete with a continuous glucose monitor and an insulin pump in Barbie's signature pink. Physicians are in short ...